Deferasirox vs placebo
AE: abnormal serum creatinine (post‐baseline) · people with non‐transfusion‐dependent thalassemia
It is very uncertain whether deferasirox changes AE: abnormal serum creatinine (post‐baseline) compared with placebo (very low certainty).
1 finding from 1 review
- Deferasirox for managing iron overload in people with thalassaemia 2017 · Cochrane Headline outcomes onlyRR 3.59 [0.19, 68.4]1 study · 166 participantsVery low